November 11, 2021 10:52 AM EST
News Briefing

Kaléo to pay out more than $12M in false claims case re­gard­ing high-priced ver­sion of cheap opi­oid over­dose an­ti­dote; Uro­Gen gets ready to start PhI­II can­cer tri­al

Paul Schloesser

Associate Editor

Vir­ginia phar­ma Kaléo has agreed to pay the Unit­ed States $12.7 mil­lion to re­solve ac­cu­sa­tions that the phar­ma caused the sub­mis­sion of false claims for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times